Two more people under China Pharmaceutical Group were investigated

March 3, 2025  Source: drugdu 142

"/On February 28, Wang Zhiguang, member of the Party Committee and deputy general manager of China Pharmaceutical and Health Products Co., Ltd. (hereinafter referred to as China Pharmaceutical and Health Products), was suspected of serious violations of discipline and law. He is currently undergoing disciplinary review and supervision investigation by the Discipline Inspection and Supervision Group of General Technology Group and the Supervision Committee of Xingshan County, Yichang City, Hubei Province; Guo Cui, former manager of the administrative department of Hubei General Pharmaceutical Co., Ltd. (hereinafter referred to as Hubei General), was suspected of serious violations of discipline and law. He is currently undergoing disciplinary review and supervision investigation by the Discipline Inspection and Supervision Group of General Technology Group and the Supervision Committee of Yiting District, Yichang City, Hubei Province.

According to Qichacha, China Pharmaceutical and Health Products is a wholly-owned subsidiary of China Pharmaceutical (600056.SH), and China Pharmaceutical indirectly holds 51% of the shares of Hubei General.

China Pharmaceutical was formerly the China Pharmaceutical and Health Products Import and Export Corporation established in 1983. It joined the General Technology Group in 1999 and is now the only pharmaceutical and medical device production and operation platform under the group. According to Wind data, as of the close of February 27, the company's stock price closed at 10.73 yuan per share, and the company's total market value was 16.1 billion yuan.

Since 2022, many people under China Pharmaceutical have been investigated.

In 2024, many senior executives of Hubei General were investigated for suspected serious violations of discipline and law, including former general manager Wang Jian, former financial director Dai Xuhui, and former assistant general manager Zhuang Awei.

In 2024, the website of the Central Commission for Discipline Inspection and the National Supervisory Commission released "Three Court Trials丨Embezzlement or Illegal Operation of Similar Businesses", reporting the case of Yang Jie, the former chairman of Shanghai General Runda Medical Technology Co., Ltd. under China Pharmaceutical. The Qinhuai District People's Court sentenced Yang Jie to three years in prison, suspended for four years, and fined 1 million yuan for the crime of illegally operating similar businesses.

From July 2007 to July 2022, Yang Jie used his position to obtain illegal profits of more than 8 million yuan while serving as deputy general manager of Hainan General Sanyo Pharmaceutical Co., Ltd. and deputy general manager of China Pharmaceutical Pharmaceutical Industry Division. Yang Jie was investigated in August 2022.

https://finance.eastmoney.com/a/202502283332820023.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.